← Home
📢 Press Releases
| Date | Press release |
|---|---|
| 2026-06-03 07:40:00 | Angelini Ventures Marks First Portfolio Company Exit As Resmed Acquires Noctrix Health For $340 Million Angelini ventures marks its first portfolio exit as resmed acquires noctrix health, validating its strategy of backing breakthrough healthcare innovation. |
| 2026-06-01 16:05:00 | Resmed Completes Acquisition Of Noctrix Health, Expanding Clinical Sleep Health Portfolio Acquisition adds nidra® tonic motor activation (tomac) therapy, an fda de novo classified, nonpharmacologic treatment designed to address moderate-to-severe restless legs syndrome (rls). acquisition adds nidra® tonic motor activation (tomac) therapy, an fda de novo classified, nonpharmacologic treatment designed to address moderate-to-severe restless legs syndrome (rls). |
| 2026-05-19 16:05:00 | Resmed Announces Participation In The 46th Annual William Blair Growth Stock Conference San diego, may 19, 2026 (globe newswire) -- resmed (nyse: rmd, asx: rmd) today announced mick farrell, chairman and chief executive officer, and aaron bloomer, chief financial officer, will attend the 46th annual william blair growth stock conference in chicago, il on tuesday, june 2, 2026. resmed’s webcast presentation will begin at approximately 4:40 p.m. (central time). |
| 2026-04-30 16:10:00 | Resmed Chief Financial Officer Brett Sandercock To Retire; Aaron Bloomer appointed As Successor San diego, april 30, 2026 (globe newswire) -- resmed (nyse: rmd, asx: rmd), the leading health technology company focused on sleep, breathing and care delivered in the home, today announced that brett sandercock, chief financial officer, plans to retire effective may 4, 2026. after conducting a comprehensive search, aaron bloomer has been appointed as his successor. |
| 2026-04-30 16:05:00 | Resmed Inc. Announces Results For The Third Quarter Of Fiscal Year 2026 Revenue increased by 11% to $1.4 billion; up 8% on a constant currency basis gaap gross margin up 290 bps to 62.2%; non-gaap gross margin up 290 bps to 62.8% gaap income from operations increased 17%; non-gaap income from operations up 18% gaap diluted earnings per share of $2.74; non-gaap diluted earnings per share of $2.86 operating cash flow of $554 million; $262 million returned to shareholders through share repurchases and dividends note: a webcast of resmed’s conference call will be available at 4:30 p.m. et today at http://investor.resmed.com san diego, april 30, 2026 (globe newswire) -- resmed inc. (nyse: rmd, asx: rmd) today announced results for its quarter ended march 31, 2026. |
| 2026-04-01 16:05:00 |
|
| 2026-03-03 03:00:00 |
|
| 2026-02-24 09:00:00 |
|
| 2026-01-29 16:05:00 |
|
| 2026-01-08 16:05:00 |
|
| 2025-12-18 16:05:00 |
|
| 2025-12-08 09:00:00 |
|
| 2025-10-30 16:05:00 |
|
| 2025-10-09 16:05:00 |
|
| 2025-09-16 16:05:00 |
|
📰 Browse additional press releases for ResMed!
Sign up for free or log in🚀 Don’t miss "The Checklist Value Investor — A Smarter Way to Pick Stocks" — free!